MIR4501: A Potential Drug Target and Biomarker (G100616137)
MIR4501: A Potential Drug Target and Biomarker
MIR4501 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and biology have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of these diseases.
MIR4501 was first identified in 2013 as a non-coding RNA molecule that was expressed in various tissues and organs, including brain, heart, and pancreas. Its function and regulation have not yet been fully understood, but its potential as a drug target and biomarker have already been identified.
One of the key features of MIR4501 is its unique structure. It is a small molecule that consists of only 19 amino acid residues and has a molecular weight of 20 kDa. Its linear shape and simple sequence make it easy to manipulate and study, which has been beneficial for its functional studies.
MIR4501 has been shown to play a role in various biological processes, including cell signaling, tissue repair, and inflammation. Its expression has been observed in various tissues and organs, including the brain, heart, and pancreas, which suggests that it may have important functions in these organs.
As a potential drug target, MIR4501 has been shown to interact with several protein molecules, including the protein known as PDGF-RG, which is a key regulator of cell signaling. MIR4501 has also been shown to interact with the protein known as NF-kappa-B, which is involved in inflammation and pain signaling.
MIR4501's potential as a drug target is based on its unique structure and its interaction with important proteins. Its small size and simple sequence make it easy to manipulate and study, which has been beneficial for its functional studies.
As a potential biomarker, MIR4501 has been shown to have potential in the diagnosis and monitoring of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been observed in various tissues and organs, including the brain, heart, and pancreas, which suggests that it may have important functions in these organs.
MIR4501 has been shown to play a role in the development and progression of cancer, including breast, ovarian, and prostate cancer. Its expression has been shown to increase in various types of cancer, which may make it an attractive target for cancer therapies.
MIR4501 has also been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Its expression has been observed in the brain, which suggests that it may have important functions in these diseases.
In addition to its potential as a drug target and biomarker, MIR4501 has also been shown to have potential in the treatment of various diseases. Its interaction with PDGF-RG and NF-kappa-B suggests that it may have potential in the treatment of diseases that are characterized by the uncontrolled growth and proliferation of cells.
In conclusion, MIR4501 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and biology have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of these diseases. Further studies are needed to fully understand its functions and potential as a drug.
Protein Name: MicroRNA 4501
The "MIR4501 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4501 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4504 | MIR4505 | MIR4506 | MIR4507 | MIR4508 | MIR4509-1 | MIR4509-2 | MIR4509-3 | MIR450A1 | MIR450A2 | MIR450B | MIR4510 | MIR4511 | MIR4512 | MIR4513 | MIR4514 | MIR4516 | MIR4519 | MIR451A | MIR451B | MIR452 | MIR4520-1 | MIR4520-2 | MIR4521 | MIR4524A | MIR4524B | MIR4525 | MIR4526 | MIR4527 | MIR4527HG | MIR4529 | MIR4530 | MIR4531 | MIR4533 | MIR4534 | MIR4535 | MIR4536-1 | MIR4536-2 | MIR4537 | MIR4538 | MIR4539 | MIR454 | MIR4540 | MIR455 | MIR4632 | MIR4633 | MIR4634 | MIR4635 | MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687 | MIR4688 | MIR4689
